Evidence map›Paper›PMID 35576916›Full record

ArticleCancer biology & therapy2022

Dramatic response to local radiotherapy in a refractory metastatic mediastinal yolk sac tumor patient harboring a germline

Xi Cheng, Haiming Yu, Jinying Li, Xiaona Han, Erhong Meng, Houqing Zhou, Dongliang Wang, Beifang Niu, Xiaotao Zhang

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xi ChengDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Haiming YuDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Jinying LiDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Xiaona HanDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.
Erhong MengDepartment of Scientific Research Project, ChosenMed Technology (Beijing) Co., Ltd, Beijing, China.
Houqing ZhouDepartment of Scientific Research Project, ChosenMed Technology (Beijing) Co., Ltd, Beijing, China.
Dongliang WangDepartment of Scientific Research Project, ChosenMed Technology (Beijing) Co., Ltd, Beijing, China.
Beifang NiuDepartment of Scientific Research Project, ChosenMed Technology (Beijing) Co., Ltd, Beijing, China.
Xiaotao ZhangDepartment of Radiation Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, China.ORCID 0000-0001-7213-4970
Qingdao University · CNChinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mediastinal yolk sac tumors (YSTs) are highly aggressive germ cell tumors with an extremely poor prognosis. Radiotherapy plays an important role in the treatment of mediastinal YSTs. To maximize benefit from radiotherapy in patients with mediastinal YSTs, exploring functionally relevant biomarkers is essential. Previous studies have demonstrated that mutations in DNA-damage repair (DDR) genes, including

Indexed as

Endodermal Sinus TumorMediastinal NeoplasmsAdultBiomarkersBRCA2 ProteinFrameshift MutationGerm-Line MutationHumansMaleBiomarkersBRCA2 ProteinBRCA2 protein, humanBRCA2case reportDNA-damage repairMediastinal yolk sac tumorsradiotherapy

Identifiers

PMID35576916
PMCPMC9116401
OpenAlexW4280546147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.